Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02528188 · ClinicalTrials.gov registry record · Phase 3
Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 3,021
- Enrollment target
NCT02528188: Completed Phase 3 study, sponsored by Pfizer.
NCT02528188 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 3,021 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (291% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02528188, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,021 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the long-term joint safety and efficacy (pain relief) of the investigational study drug, tanezumab compared to non-steroidal anti inflammatory drugs (NSAIDs) in subjects with osteoarthritis of the hips or knees.
Primary Outcome
Any participant with incidence of an adjudicated outcome of primary osteonecrosis, rapidly progressive osteoarthritis (OA) type 1 or type 2, subchondral insufficiency fracture, or pathological fracture. Rapidly progressive OA type 1 events were those that the Adjudication Committee considered to have significant loss of joint space width (JSW) (greater than or equal to \[\>=\] 2 millimeters \[mm\]) within approximately 1 year without gross structural failure. Rapidly progressive OA type 2 events
Interventions
- DRUG NSAID
- BIOLOGICAL Tanezumab 2.5 mg
- BIOLOGICAL Tanezumab 5 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,021 participants |
| Start Date | 2015-07-21 |
| Est. Completion | 2019-02-27 |
| Phase | Phase 3 |
What the finished NCT02528188 record still lists
NCT02528188 is an interventional study that assigns participants to a tested intervention. Its 3,021 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (291% higher).
The record links to 0 conditions, and to 3 interventions - of which NSAID is the first listed.
NCT02528188 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02528188 about?
NCT02528188 is a clinical study titled "Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee". The purpose of this study is to compare the long-term joint safety and efficacy (pain relief) of the investigational study drug, tanezumab compared to non-steroidal anti inflammatory drugs (NSAIDs) in subjects with osteoarthritis of the hips or knees.
What is the current status of trial NCT02528188?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,021 participants. The study started on 2015-07-21. Estimated completion is 2019-02-27.
What interventions are being tested in trial NCT02528188?
The interventions under investigation include: NSAID (DRUG), Tanezumab 2.5 mg (BIOLOGICAL), Tanezumab 5 mg (BIOLOGICAL).
Who is sponsoring clinical trial NCT02528188?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02528188's enrollment target sits among peer trials
3,021 79th of 2000 higher than 1,922 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07116967 · 3,040 participants · Phase 3
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
- NCT00004847 · 3,000 participants · Phase 1
Diagnosis of Pheochromocytoma
- NCT00478712 · 3,000 participants
Hirschsprung Disease Genetic Study
- NCT00579566 · 3,000 participants
Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI